ClinicalTrials.gg

Program

Dronedarone

Also written as “Dabigatran etexilate plus dronedarone”, “Dronedarone (SR33589)” and “Dronedarone Hydrochloride Tablets”.

Its studies are mostly in Atrial Fibrillation · Heart Failure, led by 4 companies.

Furthest: phase 4, since Dec 2, 200918 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi140 open or runningphase 4since Dec 2, 2009Sep 13, 2005none ahead
Lunan Pharmaceutical Group20 open or runningno phasesince Jan 27, 2026Jan 27, 2026none ahead
Boehringer Ingelheim10 open or runningphase 1since Feb 28, 2011Feb 28, 2011none ahead
Gilead Sciences10 open or runningphase 2since Jan 18, 2012Jan 18, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 13, 2005First study: phase 3 study in Atrial FibrillationNew to SanofiSanofi · NCT00174785 · 4,628 enrolled · United States, Argentina, Australia and more
  2. Nov 25, 20052 phase 3 studies in Atrial FibrillationSanofi · NCT00259428, NCT00259376
  3. Jun 20, 2007Phase 3 study in Atrial FibrillationSanofi · NCT00489736 · 504 enrolled · United States, Argentina, Australia and more
  4. Jun 12, 20082 phase 3 studiesSanofi · NCT00697086, NCT00696631
  5. Dec 2, 2009Phase 4 study in Atrial FibrillationSanofi · NCT01026090 · 292 enrolled · Canada
  6. Jan 12, 2010Phase 4 study in Atrial FibrillationSanofi · NCT01047566 · 183 enrolled · Netherlands
  7. May 28, 2010Phase 4 study in Atrial FibrillationSanofi · NCT01135017 · 112 enrolled · United States
  8. Jun 8, 2010Phase 4 study in Atrial FibrillationSanofi · NCT01140581 · 402 enrolled · Australia, Austria, Estonia and more
  9. Jun 22, 2010Phase 3 study in Atrial FibrillationSanofi · NCT01151137 · 3,236 enrolled · United States, Argentina, Australia and more
  10. Sep 9, 20102 phase 4 studies in Atrial FibrillationSanofi · NCT01199081, NCT01198873
  11. Sep 30, 2010Phase 2 study in Atrial FibrillationSanofi · NCT01213368 · 181 enrolled · Japan
  12. Feb 28, 2011Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT01306162 · 36 enrolled · Germany
  13. Jan 18, 2012Gilead Sciences's first study: phase 2 study in Atrial FibrillationNew to Gilead SciencesGilead Sciences · NCT01522651 · 134 enrolled · United States, Germany, Israel and more
  14. Jan 27, 2026Lunan Pharmaceutical Group's first studies: 2 no phase studies in Atrial FibrillationNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT07396519, NCT07396506

TargetBeta

“Voltage-gated L-type calcium channel blocker; Sodium channel alpha subunit blocker; Inward rectifier potassium channel 2 blocker; Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker”ChEMBL 37, by rule

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07396519Atrial Fibrillation · China–CompletedLunan Pharmaceutical GroupDec 7, 202248
NCT07396506Atrial Fibrillation · China–CompletedLunan Pharmaceutical GroupJul 10, 202351
NCT01522651Atrial Fibrillation · United States, Germany, Israel and more2CompletedGilead SciencesMar 10, 2014134
NCT01306162Healthy · Germany1CompletedBoehringer IngelheimMay 201136
NCT01213368Atrial Fibrillation · Japan2CompletedSanofiApr 2011181
NCT01199081Atrial Fibrillation · Colombia, Czech Republic, Denmark and more4CompletedSanofiApr 2012154
NCT01198873Atrial Fibrillation · United States, Canada4TerminatedSanofiJan 201276
NCT01151137Atrial Fibrillation · United States, Argentina, Australia and more3TerminatedSanofiSep 20113,236
NCT01140581Atrial Fibrillation · Australia, Austria, Estonia and more4CompletedSanofiDec 2011402
NCT01135017Atrial Fibrillation · United States4TerminatedSanofiFeb 2012112
NCT01047566Atrial Fibrillation · Netherlands4CompletedSanofiSep 2011183
NCT01026090Atrial Fibrillation · Canada4TerminatedSanofiDec 2011292
NCT00697086Atrial Fibrillation · Belgium, Czech Republic, France and more3CompletedSanofiJun 2004174
NCT00696631Heart Failure · Denmark, Hungary, Netherlands and more3TerminatedSanofiJan 2003653
NCT00489736Atrial Fibrillation · United States, Argentina, Australia and more3CompletedSanofiOct 2008504
NCT00259428Atrial Fibrillation · Belgium, Czech Republic, Denmark and more3CompletedSanofiAug 2003615
NCT00259376Atrial Fibrillation · United States, Argentina, Australia and more3CompletedSanofiSep 2003629
NCT00174785Atrial Fibrillation · United States, Argentina, Australia and more3CompletedSanofiMar 20084,628

How it is read

Names in the registry

  • “Dronedarone”, 7 entries
  • “Dabigatran etexilate plus dronedarone”, 4 entries
  • “Dronedarone (SR33589)”, 4 entries
  • “Dronedarone Hydrochloride Tablets”, 2 entries
  • “dronedarone (SR33589)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.